Loading patent…
AssigneeThe Board of Trustees of the University of Illinois
InventorZaijie Jim Wang
Estimating the term…
Drug delivery is targeted to new opioid receptors using receptor-mediated internalization. Dermorphin was successfully conjugated to DSPE-PEG3400 without affecting the affinity to its receptor. The synthesized conjugate was inserted into preformed sterically stabilized liposomes to obtain dermorphin-grafted SSL. DSPE-PEG34Qo-dermorphin and dermorphin-SSL retained their affinity and selectivity for MOR. Moreover, dermorphin-SSL and encapsulated probes were taken up by CHO-hMOR cells, but not by naive CHO cells or very closely related CHO-hDOR cells. Dermorphin-SSL can be used to deliver drugs to the intracellular component of intended cells with high fidelity. Therefore, dermorphin-SSL is useful to carry pharmaceutical agents to achieve region-specific delivery of analgesics and/or to attenuate side effects associated with opioids.
A method to target a compound to a mu opioid receptor, the method comprising:
A composition comprising:
A pharmaceutical delivery system to carry pharmaceutical agents to achieve repair-specific delivery of analgesics and/or alleviate side effects associated with mu opioids receptor activation, the system comprising:
A method to synthesize a DSPE-PEG3400 conjugated dermorphin, the method comprising:
Dependencies are inferred from the claim text.